Australia markets closed

Nephros, Inc. (NEPH)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
1.8000-0.0200 (-1.10%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 18.98M
Enterprise value 17.48M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.37
Price/book (mrq)2.39
Enterprise value/revenue 1.27
Enterprise value/EBITDA -2.16

Trading information

Stock price history

Beta (5Y monthly) 1.19
52-week change 326.76%
S&P500 52-week change 326.76%
52-week high 34.0400
52-week low 31.4000
50-day moving average 32.0074
200-day moving average 32.4954

Share statistics

Avg vol (3-month) 311.34k
Avg vol (10-day) 31.92k
Shares outstanding 510.54M
Implied shares outstanding 610.91M
Float 85.64M
% held by insiders 112.75%
% held by institutions 140.98%
Shares short (30 Aug 2024) 44.58k
Short ratio (30 Aug 2024) 40.29
Short % of float (30 Aug 2024) 40.04%
Short % of shares outstanding (30 Aug 2024) 40.04%
Shares short (prior month 31 July 2024) 43k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 310 July 2019
Ex-dividend date 4N/A
Last split factor 21:9
Last split date 310 July 2019

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)30 June 2024

Profitability

Profit margin -9.40%
Operating margin (ttm)-9.75%

Management effectiveness

Return on assets (ttm)-7.96%
Return on equity (ttm)-15.61%

Income statement

Revenue (ttm)13.77M
Revenue per share (ttm)1.31
Quarterly revenue growth (yoy)-8.30%
Gross profit (ttm)N/A
EBITDA -1.19M
Net income avi to common (ttm)-1.29M
Diluted EPS (ttm)-0.1200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)3.08M
Total cash per share (mrq)0.29
Total debt (mrq)1.58M
Total debt/equity (mrq)19.93%
Current ratio (mrq)4.06
Book value per share (mrq)0.75

Cash flow statement

Operating cash flow (ttm)-848k
Levered free cash flow (ttm)-235.88k